New radioactive tracer could spot breast cancer without a biopsy
NCT ID NCT05203497
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new radioactive tracer called 99mTc-ZHER2:41071 in 30 women with breast cancer. The tracer is designed to attach to HER2 proteins on cancer cells, allowing doctors to see them on a SPECT scan. The goal was to see how the tracer spreads in the body, how safe it is, and whether it can accurately tell HER2-positive from HER2-negative tumors compared to standard biopsy tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Technetium-99m-labeled affibody molecule (99mTc-ZHER2:41071)
What this could lead to
If successful, this could lead to a non-invasive imaging method to detect HER2-positive breast cancer, potentially reducing the need for biopsies.
What could go wrong
This is an early phase 1 study with only 30 participants, so results may not apply to all patients. The tracer's safety and accuracy are still being tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
TomskNRMC
Tomsk, Russia